Imunidade humoral e celular em indivíduos curados de leishmaniose visceral

Badaró, Roberto; Carvalho, Edgar M.; Orge, Maria de La Glória Orge; Teixeira, Rodolfo S.; Rocha, Heonir

doi:10.1590/s0037-86821985000200003

Cited by 18 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these antibodies have been observed to cross-react with antigens of other infectious agents, particularly Trypanosoma cruzi, 37 and are found in individuals with subclinical L. chagasi infection, [8][9][10] and persist after successful therapy for VL. 5,18 In the present study, the sensitivity and specificity for the anti-leishmanial IgE detection assay in diagnosing VL were 100%. More importantly, specific IgE antibodies are a marker for active disease.…”

Section: Discussionmentioning

confidence: 47%

“…[1][2][3] Failure to control intramacrophage growth of Leishmania chagasi, the causal agent of American visceral leishmaniasis (VL), leads to a severe disease associated with hepatosplenomegaly, pancytopenia, hemorrhagic complications, and increased susceptibility to microbial infections. 4 High titers of antibody are found in the course of L. chagasi infection and antibody detection is an important diagnostic tool in identifying cases of VL [5][6][7] and individuals with subclinical L. chagasi infection. [8][9][10] Only a few studies have investigated the immunoglobulin isotype responses elicited during the course of VL.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis.

Atta¹,

D'Oliveira²,

Correa³

et al. 1998

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Visceral leishmaniasis (VL) is characterized by a depression of the T helper cell type 1 immune response. Although mRNA expression for interleukin-4 (IL-4) is observed, evidence of the role of this cytokine in the pathogenesis of VL has been lacking. Since IL-4 is involved in IgE synthesis, we measured the total IgE and Leishmania antigen-specific IgE antibody levels in sera from patients with VL.

show abstract

Section: Discussionmentioning

confidence: 47%

mentioning

confidence: 99%

Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis.

Atta¹,

D'Oliveira²,

Correa³

et al. 1998

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…This T cell deficiency is manifested in vitro by failure of the T lymphocytes to proliferate after stimulation to parasite antigens [56]. Usually, these patients become responsive after resolution of their symptoms [57]. Therefore, T cell reactivity shown either in vitro (e.g.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f®+MPL-SE® vaccine to treat canine visceral leishmaniasis

Miret

Nascimento

Sampaio

et al. 2008

Vaccine

View full text Add to dashboard Cite

The evaluation of the efficacy of an immunochemotherapy protocol to treat symptomatic dogs naturally infected with Leishmania chagasi was studied. This clinical trial had the purpose to test the combination of N-methyl meglumine antimoniate (Glucantime and the second generation recombinant vaccine Leish-110f plus the adjuvant MPL-SE to treat the canine leishmaniasis (CanL). Thirty symptomatic naturally infected mongrel dogs were divided into five groups. Animals received standard treatment with Glucantime or treatment with Glucantime Leish-110f + MPL-SEas immunochemotherapy protocol. Additional groups received Leish-110f + MPL-SE only, MPL-SE only, or placebo. Evaluation of haematological, biochemical (renal and hepatic function) and plasmatic proteins, immunological (humoral and cellular immune response) and the parasitological test revealed improvement of the clinical parameters and parasitological cure in dogs in both chemotherapy alone and immunochemotherapy cohorts. However, the immunotherapy and immunochemotherapy cohorts had reduced number of deaths, higher survival probability, and specific cellular reactivity to leishmanial antigens, in comparison with chemotherapy cohort only and control groups (adjuvant alone and placebo). These results support the notion of using well-characterized recombinant vaccine as an adjunct to improve the current chemotherapy of CanL.

show abstract

“…The disease is characterized by fever, hepatomegaly, massive splenomegaly, and pancytopenia (31). The humoral immune response in patients with active KA is marked by the production of specific and nonspecific circulating antibodies (8,10,19,26,39). Both immunoglobulin G (IgG) and IgM levels are increased, with IgG varying in persistency, while IgM levels increase as the infection progresses but fall rapidly after treatment (13).…”

mentioning

confidence: 99%

Persistence of elevated levels of galactosyl-alpha(1-3)galactose antibodies in sera from patients cured of visceral leishmaniasis

1988

View full text Add to dashboard Cite

Using rabbit erythrocyte-derived neutral glycosphingolipids enriched for a ceramide pentasaccharide as the antigen, we detected elevated anti-galactosyl-alpha(1-3)galactose (anti-G alpha G) antibody levels in 76% of children with active visceral leishmaniasis (kala-azar [KA]) and in 42% of clinically cured patients with KA who had been treated about 5 years previously with meglumine antimonate (30 mg/kg in a series of 15 daily injections). The long-term persistence of elevated G alpha G antibodies was also found in 56% of children living in the same geographic zone who, at the time of the initial clinical examination, had fever and evident splenomegaly with hyperglobulinemia but a negative bone marrow aspirate for leishmanial bodies. Five years after antimonate treatment, these clinically cured children with presumptive KA were studied serologically. Their mean G alpha G antibody values were slightly lower than those in patients with active KA but were still abnormal. Using different biochemical and immunological approaches, we found that elevated G alpha G antibodies present in patients with KA bound specifically to glycoconjugates with an alpha(1-3)-terminal galactose residue. G alpha G antibodies were mainly distributed between immunoglobulin classes G and M in patients with active KA and in antimonate-treated patients with clinically cured KA. The possibility of the existence of remnant living parasites or the persistence of inserted G alpha G epitopes in parasitized macrophages was proposed as a mechanism to explain the long-term persistence of abnormal G alpha G antibodies in patients apparently cured of KA.

show abstract

Imunidade humoral e celular em indivíduos curados de leishmaniose visceral

Cited by 18 publications

References 20 publications

Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis.

Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis.

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f®+MPL-SE® vaccine to treat canine visceral leishmaniasis

Persistence of elevated levels of galactosyl-alpha(1-3)galactose antibodies in sera from patients cured of visceral leishmaniasis

Contact Info

Product

Resources

About